EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells

Herui Wang iD, Rogelio Medina, Juan Ye, Yaping Zhang, Samik Chakraborty, Alex Valenzuela, Ondrej Uher, Katerina Hadrava Vanova, Mitchell Sun, Xueyu Sang, Deric M Park, Jan Zenka und 3 weitere

Advanced Science · 2024-04 · 11 (14)

DOI: 10.1002/advs.202308280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.01.2024. Verfasst von Herui Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 10022, USA. Hauptthemen laut MEDLINE: Glioblastoma, Vaccines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Programs of the National Institutes of Health (NIH), including the National Cancer Institute (NCI) and the Eunice Kennedy Shriver National….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite strides in immunotherapy, glioblastoma multiforme (GBM) remains challenging due to low inherent immunogenicity and suppressive tumor microenvironment. Converting “cold” GBMs to “hot” is crucial for immune activation and improved outcomes. This study comprehensively characterized a therapeutic vaccination strategy for preclinical GBM models. The vaccine consists of Mannan‐BAM‐anchored irradiated whole tumor cells, Toll‐like receptor ligands [lipoteichoic acid (LTA), polyinosinic‐polycytidylic acid (Poly (I:C)), and resiquimod (R‐848)], and anti‐CD40 agonistic antibody (rWTC‐MBTA). Intracranial GBM models (GL261, SB28 cells) are used to evaluate the vaccine efficacy. A substantial number of vaccinated mice exhibited complete regression of GBM tumors in a T‐cell‐dependent manner, with no significant toxicity. Long‐term tumor‐specific immune memory is confirmed upon tumor rechallenge. In the vaccine‐draining lymph nodes of the SB28 model, rWTC‐MBTA vaccination triggered a major rise in conventional dendritic cell type 1 (cDC1) 12 h post‐treatment, followed by an increase in conventional dendritic cell type 2 (cDC2), monocyte‐derived dendritic cell (moDC), and plasmacytoid dendritic cell (pDC) on Day 5 and Day 13. Enhanced cytotoxicity of CD4+ and CD8+ T cells in vaccinated mice is verified in co‐culture with tumor cells. Analyses of immunosuppressive signals (T‐cell exhaustion, myeloid‐derived suppressor cells (MDSC), M2 macrophages) in the GBM microenvironment suggest potential combinations with other immunotherapies for enhanced efficacy. In conclusion, the authors findings demonstrate that rWTC‐MBTA induces potent and long‐term adaptive immune responses against GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaVaccinesMiceAnimalsCD8-Positive T-LymphocytesDendritic CellsImmunityTumor Microenvironment

Stichwörter der Autor:innen

dendritic cellsglioblastomaimmunotherapyrWTC‐MBTA vaccinetumor microenvironment

Substanzen

Vaccines

Autor:innen und Institutionen

  • Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 10022, USA.
  • NE1 Inc., New York, NY, 10022, USA.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD, 20892, USA.
  • John Theurer Cancer Center, HUMC, Hackensack Meridian School of Medicine, 92 2nd St, Hackensack, NJ, 07601, USA.
  • Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, 37005, Czech Republic.

ORCID-Profile: Herui Wang, Zhengping Zhuang

Förderung

  • Intramural Research Programs of the National Institutes of Health (NIH), including the National Cancer Institute (NCI) and the Eunice Kennedy Shriver National…

Zitieren

APA

Wang, H., Medina, R., Ye, J., Zhang, Y., Chakraborty, S., Valenzuela, A., Uher, O., Hadrava Vanova, K., Sun, M., Sang, X., Park, D. M., Zenka, J., Gilbert, M. R., Pacak, K., & Zhuang, Z. (2024). rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells. Advanced Science, 11(14). https://doi.org/10.1002/advs.202308280

Vancouver

Wang H, Medina R, Ye J, Zhang Y, Chakraborty S, Valenzuela A, et al. rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells. Advanced Science. 2024;11(14). doi:10.1002/advs.202308280

BibTeX
@article{Wang2024,
  author = {Wang, Herui and Medina, Rogelio and Ye, Juan and Zhang, Yaping and Chakraborty, Samik and Valenzuela, Alex and Uher, Ondrej and Hadrava Vanova, Katerina and Sun, Mitchell and Sang, Xueyu and Park, Deric M and Zenka, Jan and Gilbert, Mark R and Pacak, Karel and Zhuang, Zhengping},
  title = {rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {14},
  doi = {10.1002/advs.202308280}
}
Kostenlos starten →